423 related articles for article (PubMed ID: 33387667)
1. Risk of Serious Infections With Vedolizumab Versus Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Disease.
Kirchgesner J; Desai RJ; Beaugerie L; Schneeweiss S; Kim SC
Clin Gastroenterol Hepatol; 2022 Feb; 20(2):314-324.e16. PubMed ID: 33387667
[TBL] [Abstract][Full Text] [Related]
2. Comparative Risk of Serious Infections With Tumor Necrosis Factor α Antagonists vs Vedolizumab in Patients With Inflammatory Bowel Diseases.
Singh S; Heien HC; Herrin J; Dulai PS; Sangaralingham L; Shah ND; Sandborn WJ
Clin Gastroenterol Hepatol; 2022 Feb; 20(2):e74-e88. PubMed ID: 33640480
[TBL] [Abstract][Full Text] [Related]
3. Safety and Efficacy of Vedolizumab Versus Tumor Necrosis Factor α Antagonists in an Elderly IBD Population: A Single Institution Retrospective Experience.
Pabla BS; Alex Wiles C; Slaughter JC; Scoville EA; Dalal RL; Beaulieu DB; Schwartz DA; Horst SN
Dig Dis Sci; 2022 Jul; 67(7):3129-3137. PubMed ID: 34268660
[TBL] [Abstract][Full Text] [Related]
4. Drug survival of anti-TNF agents compared with vedolizumab as a second-line biological treatment in inflammatory bowel disease: results from nationwide Swedish registers.
Rundquist S; Sachs MC; Eriksson C; Olén O; Montgomery S; Halfvarson J;
Aliment Pharmacol Ther; 2021 Feb; 53(4):471-483. PubMed ID: 33340426
[TBL] [Abstract][Full Text] [Related]
5. Vedolizumab Is Associated With a Lower Risk of Serious Infections Than Anti-Tumor Necrosis Factor Agents in Older Adults.
Kochar B; Pate V; Kappelman MD; Long MD; Ananthakrishnan AN; Chan AT; Sandler RS
Clin Gastroenterol Hepatol; 2022 Jun; 20(6):1299-1305.e5. PubMed ID: 34481954
[TBL] [Abstract][Full Text] [Related]
6. Multi-Center Experience of Vedolizumab Effectiveness in Pediatric Inflammatory Bowel Disease.
Singh N; Rabizadeh S; Jossen J; Pittman N; Check M; Hashemi G; Phan BL; Hyams JS; Dubinsky MC
Inflamm Bowel Dis; 2016 Sep; 22(9):2121-6. PubMed ID: 27542130
[TBL] [Abstract][Full Text] [Related]
7. Comparative Safety and Effectiveness of Biologic Therapy for Crohn's Disease: A CA-IBD Cohort Study.
Singh S; Kim J; Luo J; Paul P; Rudrapatna V; Park S; Zheng K; Syal G; Ha C; Fleshner P; McGovern D; Sauk JS; Limketkai B; Dulai PS; Boland BS; Eisenstein S; Ramamoorthy S; Melmed G; Mahadevan U; Sandborn WJ; Ohno-Machado L
Clin Gastroenterol Hepatol; 2023 Aug; 21(9):2359-2369.e5. PubMed ID: 36343846
[TBL] [Abstract][Full Text] [Related]
8. Comparative Outcomes and Safety of Vedolizumab vs Tumor Necrosis Factor Antagonists for Older Adults With Inflammatory Bowel Diseases.
Singh S; Iversen AT; Allin KH; Jess T
JAMA Netw Open; 2022 Sep; 5(9):e2234200. PubMed ID: 36178685
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness and safety of vedolizumab in a matched cohort of elderly and nonelderly patients with inflammatory bowel disease: the IG-IBD LIVE study.
Pugliese D; Privitera G; Crispino F; Mezzina N; Castiglione F; Fiorino G; Laterza L; Viola A; Bertani L; Caprioli F; Cappello M; Barberio B; Ricci C; Balestrieri P; Daperno M; Pluchino D; Rizzello F; Scribano ML; Sablich R; Pastorelli L; Manguso F; Variola A; Di Sario A; Grossi L; Armuzzi A;
Aliment Pharmacol Ther; 2022 Jul; 56(1):95-109. PubMed ID: 35876062
[TBL] [Abstract][Full Text] [Related]
10. Vedolizumab or Tumor Necrosis Factor Antagonist Use and Risk of New or Recurrent Cancer in Patients With Inflammatory Bowel Disease With Prior Malignancy: A Retrospective Cohort Study.
Vedamurthy A; Gangasani N; Ananthakrishnan AN
Clin Gastroenterol Hepatol; 2022 Jan; 20(1):88-95. PubMed ID: 33065312
[TBL] [Abstract][Full Text] [Related]
11. Systematic Review and Meta-Analysis: Preoperative Vedolizumab and Postoperative Complications in Patients with IBD.
Moosvi Z; Duong JT; Bechtold ML; Nguyen DL
South Med J; 2021 Feb; 114(2):98-105. PubMed ID: 33537791
[TBL] [Abstract][Full Text] [Related]
12. Safety and effectiveness of vedolizumab in paediatric patients with inflammatory bowel disease: an observational multicentre Spanish study.
Garcia-Romero R; Martinez de Zabarte Fernandez JM; Pujol-Muncunill G; Donat-Aliaga E; Segarra-Cantón O; Irastorza-Terradillos I; Medina-Benitez E; Ruiz-Hernández CJ; Carrillo-Palau M; Ros-Arnal I; Rodriguez-Martínez A; Escartin-Madurga L; Gutiérrez-Junquera C; Vicente-Santamaría S; Velasco Rodriguez-Belvis M; Fernández-Fernández S; Alberto-Alonso JR; Montraveta M; Torres-Peral R; Navalon-Rubio M; Navas-López VM; Martin de Carpi J
Eur J Pediatr; 2021 Sep; 180(9):3029-3038. PubMed ID: 33880650
[TBL] [Abstract][Full Text] [Related]
13. Risk of Malignancy with Vedolizumab Versus Tumor Necrosis Factor-α Antagonists in Patients with Inflammatory Bowel Diseases.
Singh S; Heien HC; Sangaralingham L; Shah ND; Sandborn WJ
Dig Dis Sci; 2022 Jun; 67(6):2510-2516. PubMed ID: 34085174
[TBL] [Abstract][Full Text] [Related]
14. Factors influencing the outcome of vedolizumab treatment: Real-life data with objective outcome measurements.
Mader O; Juillerat P; Biedermann L; Michetti P; Hruz P; Pittet V; Rogler G; Zahnd-Straumann N; Seibold F
United European Gastroenterol J; 2021 Apr; 9(3):398-406. PubMed ID: 33203339
[TBL] [Abstract][Full Text] [Related]
15. Comparative Safety and Effectiveness of Vedolizumab to Tumor Necrosis Factor Antagonist Therapy for Ulcerative Colitis.
Lukin D; Faleck D; Xu R; Zhang Y; Weiss A; Aniwan S; Kadire S; Tran G; Rahal M; Winters A; Chablaney S; Koliani-Pace JL; Meserve J; Campbell JP; Kochhar G; Bohm M; Varma S; Fischer M; Boland B; Singh S; Hirten R; Ungaro R; Lasch K; Shmidt E; Jairath V; Hudesman D; Chang S; Swaminath A; Shen B; Kane S; Loftus EV; Sands BE; Colombel JF; Siegel CA; Sandborn WJ; Dulai PS
Clin Gastroenterol Hepatol; 2022 Jan; 20(1):126-135. PubMed ID: 33039584
[TBL] [Abstract][Full Text] [Related]
16. Comparative Risk of Serious Infections With Biologic Agents and Oral Small Molecules in Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis.
Solitano V; Facciorusso A; Jess T; Ma C; Hassan C; Repici A; Jairath V; Armuzzi A; Singh S
Clin Gastroenterol Hepatol; 2023 Apr; 21(4):907-921.e2. PubMed ID: 35944832
[TBL] [Abstract][Full Text] [Related]
17. Infectious risk of vedolizumab compared with other biological agents in the treatment of inflammatory bowel disease.
Innocenti T; Roselli J; Lynch EN; Apolito P; Parisio L; Bagnoli S; Macrì G; Rogai F; Tarocchi M; Milani S; Galli A; Milla M; Dragoni G
Eur J Gastroenterol Hepatol; 2021 Dec; 33(1S Suppl 1):e574-e579. PubMed ID: 35048649
[TBL] [Abstract][Full Text] [Related]
18. Outcome of elective switching to vedolizumab in inflammatory bowel disease patients under tumor necrosis factor antagonist-maintained clinical remission.
Wang Y; Wang J; Pekow J; Dalal S; Cohen RD; Ollech J; Israel A; Shogan BD; Micic D; Cannon L; Umanskiy K; Hurst R; Hyman N; Rubin DT; Sakuraba A
J Gastroenterol Hepatol; 2019 Dec; 34(12):2090-2095. PubMed ID: 31169926
[TBL] [Abstract][Full Text] [Related]
19. Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysis.
Peyrin-Biroulet L; Arkkila P; Armuzzi A; Danese S; Guardiola J; Jahnsen J; Lees C; Louis E; Lukáš M; Reinisch W; Roblin X; Jang M; Byun HG; Kim DH; Lee SJ; Atreya R
BMC Gastroenterol; 2022 Jun; 22(1):291. PubMed ID: 35676620
[TBL] [Abstract][Full Text] [Related]
20. Second-Line Biologic Therapy Following Tumor Necrosis Factor Antagonist Failure: A Real-World Propensity Score-Weighted Analysis.
Ibing S; Cho JH; Böttinger EP; Ungaro RC
Clin Gastroenterol Hepatol; 2023 Sep; 21(10):2629-2638. PubMed ID: 36787837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
